Floatz logo

Inno-206

Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

Rutgers, The State University of New JerseyPhase 2Active
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
81/ 100

Competitive context

33 Active assets in the Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Yazeed Sawalha
Phase 2B
Ibrutinib
National Cancer Institute (NCI)
Phase 2B
PREDNISONE TABLETS
National Cancer Institute (NCI)
Phase 2B
Cyclophosphamide
Mayo Clinic
Phase 2B
ETOPOSIDE
David Bond, MD
Phase 2B

View all 39 →

Same molecule, other indications

Inno-206 is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →
plasma cell myelomaDormant
BBB
Indicative ·
77 / 100
View asset →
Recurrent Adult Acute Lymphoblastic LeukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →